Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
Pancreatic Cancer Symptoms: Vital Blood Markers
Pancreatic Cancer Symptoms: Vital Blood Markers 4

Finding pancreatic cancer early is hard because its symptoms are not clear. Also, blood tests can’t always catch it. This can worry patients a lot.

We at our place are all about top-notch healthcare. We help patients from all over. New blood tests are making it easier to find cancer early. This gives patients new hope.

We’ll look into how pancreatic cancer can show up in blood tests. We’ll also talk about the latest in this area. We want to give you the info and support you need.

Key Takeaways

  • Early diagnosis of pancreatic cancer is challenging due to vague symptoms.
  • Traditional blood tests have limitations in detecting early-stage disease.
  • Cutting-edge blood tests are improving the outlook for timely diagnosis.
  • Our institution is dedicated to providing world-class healthcare for international patients.
  • Staying informed about the latest advancements can provide hope and support for patients.

The Challenge of Detecting Pancreatic Cancer

The Challenge of Detecting Pancreatic Cancer
Pancreatic Cancer Symptoms: Vital Blood Markers 5

Pancreatic cancer is hard to find early because its first signs are vague. This makes it tough for doctors to catch it when it’s small.

Why Early Detection is Difficult

Finding pancreatic cancer early is tough for a few reasons. First, the symptoms are not clear and can look like other, less serious problems. This means people might not get checked right away. By the time they do, the cancer might have grown a lot.

The pancreas is deep inside the belly, making it hard to feel tumors. So, doctors usually use scans and blood tests to find it.

Key challenges in early detection include:

  • Non-specific symptoms
  • Late presentation due to lack of early warning signs
  • Difficulty in detecting tumors through physical examination

The Importance of Blood Testing

Blood tests are now key in finding pancreatic cancer. New tests can spot the disease better than before.

These tests look for markers like CA19-9 in the blood. They’re not perfect but help a lot when used with scans.

“The development of novel blood-based assays represents a significant step forward in the diagnosis of pancreatic cancer.”

Expert Opinion

Using blood tests with other methods can make diagnosing pancreatic cancer more accurate. This might help find the disease sooner.

Understanding Pancreatic Cancer

Understanding Pancreatic Cancer
Pancreatic Cancer Symptoms: Vital Blood Markers 6

Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic cancer. It starts in the pancreas’s ducts. It’s aggressive and has a poor prognosis.

What is Pancreatic Ductal Adenocarcinoma (PDAC)

PDAC makes up about 90% of pancreatic cancer cases. It grows in the pancreatic ducts and spreads quickly. The PAC-MANN test finds changes in protease activity, a sign of PDAC.

“The PAC-MANN test has been a big step forward in catching pancreatic cancer early.” This test is promising. It can spot PDAC with a simple blood test, which could save lives.

Risk Factors and Prevalence

Many things can increase your risk of pancreatic cancer:

  • Age: Most cases happen in people over 65.
  • Smoking: It doubles your risk.
  • Family history: Having a first-degree relative with pancreatic cancer.
  • Genetic syndromes: Certain genetic conditions like BRCA2 mutations.
  • Chronic pancreatitis: Long-term inflammation of the pancreas.

Knowing these risk factors helps with early detection and prevention.

Impact on Pancreatic Function

Pancreatic cancer, like PDAC, affects the pancreas’s function. The pancreas is key for digestion and glucose control. Cancer can cause symptoms like jaundice, weight loss, and diabetes.

The effects on pancreatic function can be severe. They impact digestion and metabolic health. It’s important to monitor and manage these effects for patient care.

Understanding pancreatic cancer is vital. Early detection and good care are essential for better outcomes. Tests like PAC-MANN are helping in this fight.

Pancreatic Cancer Symptoms

It’s important to spot the early signs of pancreatic cancer to get medical help quickly. The symptoms can be hard to notice and might seem like other health issues. This makes it tough to catch the cancer early.

Common Early Warning Signs

Early signs of pancreatic cancer include stomach pain, losing a lot of weight, and jaundice. Stomach pain is a big one because the tumor can put pressure on nearby parts, causing pain.

Common symptoms include:

  • Abdominal pain that radiates to the back
  • Unexplained weight loss
  • Jaundice (yellowing of the skin and eyes)
  • Loss of appetite
  • Digestive problems

Differences in Symptoms Between Men and Women

Men and women with pancreatic cancer show similar symptoms, but there are some differences. Women often notice jaundice first, while men might feel more stomach pain.

Symptom

Men

Women

Abdominal Pain

More frequent

Less frequent

Jaundice

Less frequent

More frequent

Weight Loss

Common

Common

Why Symptoms Are Often Overlooked

The symptoms of pancreatic cancer are often not clear and can be mistaken for other, less serious problems. This can cause a delay in finding out what’s really wrong.

Early detection requires a high index of suspicion, specially in people with risk factors for pancreatic cancer.

Traditional Blood Tests for Pancreatic Cancer

Looking for early signs of pancreatic cancer has led to blood tests. These tests are key in finding the disease, but they have their limits.

CA19-9 Tumor Marker

The CA19-9 test is a common tool for pancreatic cancer. It checks for the CA19-9 protein in your blood. This protein is higher in people with pancreatic cancer.

But, high CA19-9 levels can also mean other health issues like pancreatitis or bile duct problems. We use CA19-9 to see how the disease is doing and if treatments are working. Yet, it’s not perfect for catching cancer early.

CEA and Other Common Markers

Carcinoembryonic antigen (CEA) is another marker found in blood tests. It can be high in pancreatic cancer, but it’s not specific to it. Other markers like CA-125 and Span-1 are also being studied for pancreatic cancer detection.

Using these markers together might help improve diagnosis. But, we need more research to know for sure.

Limitations of Traditional Blood Tests

Tests like CA19-9 and CEA have big challenges in finding pancreatic cancer early. They’re not very good at catching it in its early stages. This makes them not so useful for screening everyone.

We’re always looking for better ways to find cancer early. The flaws in current tests show we need to keep researching new markers and ways to diagnose.

The Role of CA19-9 in Pancreatic Cancer Detection

CA19-9 is a key marker for pancreatic cancer. It helps doctors diagnose and track the disease. This protein is found in higher amounts in the blood of those with pancreatic cancer.

How CA19-9 Works

The CA19-9 blood test checks for this protein in the blood. High levels might mean pancreatic cancer, but they can also show other issues like pancreatitis. The test is not definitive on its own but is used alongside other diagnostic tools.

Sensitivity and Specificity Issues

CA19-9 has its limits. Not all pancreatic cancer patients have high CA19-9 levels. Some without cancer might have high levels too. This makes it less reliable as a single test.

When CA19-9 Testing is Recommended

Doctors usually recommend CA19-9 tests to track treatment progress and catch any cancer return. It’s also used with other tests to help diagnose pancreatic cancer.

CA19-9 Level

Possible Indication

Next Steps

Normal

No indication of pancreatic cancer or other related conditions.

Continue monitoring or other diagnostic tests as necessary.

Elevated

Possible pancreatic cancer or other conditions like pancreatitis.

Further diagnostic testing, such as imaging or biopsy.

Very High

Potential advanced pancreatic cancer or significant bile duct obstruction.

Comprehensive evaluation, including imaging and potentially surgery or other treatments.

Knowing how CA19-9 helps in finding pancreatic cancer is key for patients and doctors. It’s not perfect, but it’s a valuable tool in diagnosis and tracking.

Other Laboratory Tests Used in Diagnosis

Many tests, not just blood tests, help find pancreatic cancer. These tests check the patient’s health, look for problems, and help decide treatment.

Liver Function Tests

Liver function tests (LFTs) check for liver disease. Pancreatic cancer can harm the liver, so these tests are key. They look at enzymes and proteins in the blood, like ALT, AST, ALP, and bilirubin.

Liver Function Tests:

Test

Normal Range

Significance in Pancreatic Cancer

ALT

0-40 U/L

Elevated levels may indicate liver damage

AST

0-40 U/L

Elevated levels can signify liver or heart damage

ALP

30-120 U/L

High levels may indicate liver or bone disease

Bilirubin

0.1-1.2 mg/dL

Elevated levels can cause jaundice, indicating liver dysfunction or bile duct obstruction

Complete Blood Count (CBC)

A Complete Blood Count (CBC) checks the blood’s health. It looks at red and white blood cells, hemoglobin, hematocrit, and platelets. It’s not specific to pancreatic cancer but can show signs of infection, inflammation, or anemia.

Glucose Tolerance Tests

Glucose tolerance tests check how well the body handles sugar. They’re important because pancreatic cancer can mess with insulin production, causing diabetes or abnormal blood sugar.

Pancreatic Enzyme Tests

Pancreatic enzyme tests measure enzymes like amylase and lipase. High levels can mean pancreatitis or other pancreatic issues, which might be linked to pancreatic cancer.

Together, these tests help doctors understand a patient’s condition better and make accurate diagnoses.

Breakthrough: The PAC-MANN Blood Test

Development at Oregon Health & Science University

Scientists at Oregon Health & Science University created the PAC-MANN test. Their hard work led to a new way to find pancreatic cancer with a simple blood test. This could change how we screen for pancreatic cancer.

How the PAC-MANN Test Works

The PAC-MANN test looks at a small blood sample for changes in protease activity. Protease changes can mean pancreatic cancer. This test might help find cancer early.

Detecting Protease Activity Changes

The test’s main strength is finding protease activity changes. Proteases are important in our bodies, and changes can mean cancer. The PAC-MANN test uses this to tell cancer from non-cancer.

98% Accuracy in Distinguishing Cancer Cases

The PAC-MANN test is very accurate, with a 98% success rate. It can tell cancer from non-cancer very well. This makes it a great tool for doctors and patients. For more details, check out studies in medical journals like.

Advantages of the PAC-MANN Test

The PAC-MANN test is a new way to screen for pancreatic cancer. It has features that make it better than old methods.

Minimal Blood Sample Requirements

The PAC-MANN test only needs a tiny bit of blood, just 8 microliters. This is good news for patients who don’t like getting blood tests. It’s also great for those who need tests often.

The minimal blood requirement also makes it easier to test in places where getting more blood is hard.

Rapid Results Within 45 Minutes

The PAC-MANN test gives rapid results within 45 minutes. This is fast, which is important for patients who need quick answers.

“The PAC-MANN test represents a major breakthrough in our fight against pancreatic cancer, giving hope for early detection and better treatments.”

Cost-Effectiveness and Accessibility

The PAC-MANN test is not just fast, but also cost-effective. It needs less blood and is simpler to do. This makes it easier for more people to get tested.

This is key for making pancreatic cancer screening available to more people, even in places with less money for healthcare.

Benefits for Underserved Communities

The PAC-MANN test helps underserved communities a lot. These places often don’t have access to the latest medical tests. The test’s small needs and low cost are perfect for these areas.

By making it easier to find pancreatic cancer, we can help everyone, no matter where they are or who they are. This can help close the health gap.

Combining Blood Tests for Better Detection

Using different blood tests together is a new way to find pancreatic cancer early. This method uses many biomarkers and tests. It could make finding cancer more accurate and cut down on false negatives.

PAC-MANN and CA19-9 Together

Using the PAC-MANN test with the CA19-9 blood test is a big step forward. The PAC-MANN test looks for changes in protease activity. It works well with CA19-9, a common tumor marker in blood tests for pancreatic cancer.

Research shows these tests together can find more cases of pancreatic cancer. The PAC-MANN test is very good at finding cancer biomarkers. CA19-9 is known for tracking pancreatic cancer. Together, they make a strong team for diagnosis.

85% Accuracy in Early-Stage Detection

One great thing about using PAC-MANN and CA19-9 together is how well they work early on. Studies say this combo can find pancreatic cancer with 85% accuracy when it’s easier to treat.

  • This method makes finding cancer more sensitive.
  • It also lowers the chance of false negatives, which is key for early treatment.
  • This new way of screening could change how we find pancreatic cancer.

Future Combination Approaches

As research keeps going, we expect even better ways to find pancreatic cancer. We might see more biomarkers and tests added to improve accuracy.

Some ideas for future research include:

  1. Adding PAC-MANN and CA19-9 with new biomarkers.
  2. Creating algorithms to mix results from different tests.
  3. Looking into how artificial intelligence can help with complex test data.

By keeping up with new blood test combinations, we can find cancer sooner. This could lead to better treatment and outcomes for patients with pancreatic cancer.

What to Expect During Pancreatic Cancer Blood Testing

If you’re getting a pancreatic cancer blood test, you might have questions. We get it; tests can make you nervous. We’re here to help you understand what’s happening.

Preparation for Blood Tests

Your doctor might tell you how to prepare for the test. You might need to fast or skip some medicines. It’s important to follow these steps to get accurate results.

Key Preparation Steps:

  • Follow fasting instructions if required
  • Inform your healthcare provider about any medications you’re taking
  • Arrive at the testing facility at the scheduled time

The Testing Process

The test usually takes a blood sample from your arm. It’s quick and simple. A healthcare professional will clean the area, draw the blood, and then bandage it.

The blood test is a key step in finding pancreatic cancer. It’s done in a clinical setting.

Test Component

Description

Significance

CA19-9 Tumor Marker

Measures the level of CA19-9 protein in the blood

Elevated levels may indicate pancreatic cancer

Complete Blood Count (CBC)

Evaluates various components of the blood

Helps assess overall health and detect abnormalities

Liver Function Tests

Assesses liver health through various markers

Important for understanding the liver’s role in cancer diagnosis

Understanding Your Test Results

After the test, the sample goes to a lab for analysis. Your doctor will talk to you about the results. They might show markers linked to pancreatic cancer, but more tests are needed to confirm.

Understanding the results involves:

  • Interpreting the levels of various markers
  • Discussing the implications of the results with your healthcare provider
  • Determining the next steps in the diagnostic process

Next Steps After Testing

Based on your results, your doctor might suggest more tests. This could include imaging or a biopsy to confirm cancer. If it’s cancer, a treatment plan will be made based on the type and stage.

We know the process can be tough and emotional. Our team is here to support and care for you every step of the way.

Beyond Blood Tests: A Complete Diagnostic Approach

Blood tests are important, but they’re not enough to diagnose pancreatic cancer accurately. A complete approach uses many tools and techniques. This helps doctors find the disease and plan the best treatment.

Imaging Tests

Imaging tests are key in finding pancreatic cancer. They show the tumor’s size, location, and if it has spread. This information is vital for treatment.

Common imaging tests include:

  • Computed Tomography (CT) scans, which provide detailed cross-sectional images of the pancreas and surrounding areas.
  • Magnetic Resonance Imaging (MRI), which offers high-resolution images of the pancreas and can help identify tumors.
  • Endoscopic Ultrasound (EUS), a specialized ultrasound test that involves inserting an endoscope into the stomach to obtain detailed images of the pancreas.

A leading oncologist says, “Imaging tests are essential for staging pancreatic cancer and determining the best course of treatment.”

“The information gained from imaging tests is critical for developing a personalized treatment plan that addresses the specific needs of each patient.”

Endoscopic Procedures

Endoscopic procedures are also vital for diagnosing pancreatic cancer. They are less invasive and let doctors see the pancreas and nearby areas directly.

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a procedure that involves inserting a flexible tube through the mouth and into the stomach to inject dye into the pancreatic and bile ducts. This helps identify any blockages or abnormalities in these ducts.

Biopsy and Tissue Analysis

A biopsy takes a tissue sample from the pancreas for microscopic examination. It’s often the final step to confirm pancreatic cancer.

Tissue analysis can provide valuable information about:

  • The type of cancer cells present.
  • The grade of the tumor, which indicates how aggressive the cancer is likely to be.
  • Genetic mutations that may be driving the cancer’s growth.

Integrated Diagnostic Pathways

An integrated diagnostic pathway combines different tests and procedures for a full understanding of the patient’s condition. This ensures a well-rounded treatment plan.

By using imaging tests, endoscopic procedures, biopsy results, and other diagnostic information, doctors can tailor treatments to each patient’s needs.

The benefits of integrated diagnostic pathways include:

  1. More accurate diagnosis and staging of pancreatic cancer.
  2. Improved treatment planning and patient outcomes.
  3. Enhanced patient care through a multidisciplinary approach.

Monitoring Treatment Effectiveness Through Blood Work

Blood tests are key for diagnosing and tracking pancreatic cancer treatment. They help us see if the treatment is working and if we need to make changes.

Tracking Protease Activity Post-Surgery

The PAC-MANN test shows promise for monitoring treatment success post-surgery by detecting small changes in protease activity, thereby providing important insights.

Key Benefits of PAC-MANN Test:

  • Early detection of treatment response
  • Monitoring of protease activity changes
  • Potential for adjusting treatment plans

Blood Markers During Chemotherapy

During chemotherapy, we watch blood markers like CA19-9 closely. A drop in CA19-9 levels usually means the treatment is working well.

Blood Marker

Significance

CA19-9

Commonly used to monitor treatment response during chemotherapy

CEA

May be used in conjunction with CA19-9 for monitoring

Long-term Monitoring Protocols

Long-term monitoring includes regular blood tests to keep track of the patient’s health. This is vital for catching any signs of cancer coming back or spreading early.

“Regular monitoring allows us to catch any changes in the patient’s condition early, enabling timely interventions.”

 

Using the latest in blood testing helps us give more tailored care to pancreatic cancer patients. Adding tests like PAC-MANN to treatment plans is a big step forward in cancer care.

Conclusion

Early detection and diagnosis of pancreatic cancer are key to effective treatment. We’ve looked at the challenges and progress in finding this cancer. The PAC-MANN test is a new blood test that shows great promise in finding this cancer accurately.

The PAC-MANN test was made at Oregon Health & Science University. It’s a simple test that only needs a small blood sample. It gives quick results in 45 minutes. This test is 98% accurate in spotting cancer.

Using the PAC-MANN test with other markers like CA19-9 can make early detection even better. This combo has an 85% accuracy rate. It gives hope to those fighting this disease. Moving forward, using advanced blood tests will be vital in improving treatment results.

FAQ

What are the early warning signs of pancreatic cancer?

Early signs of pancreatic cancer can be tricky to spot. They might include stomach pain, losing weight, jaundice, and changes in bowel habits. Spotting these signs early is key to catching the disease.

How is pancreatic cancer diagnosed?

Doctors use several methods to diagnose pancreatic cancer. These include blood tests, imaging, endoscopy, and biopsies. Tests like CA19-9 and the PAC-MANN test are important for finding the disease.

What is the role of CA19-9 in pancreatic cancer detection?

CA19-9 is a marker used to detect pancreatic cancer. But, it’s not always reliable for catching the disease early. It’s often used with other tests for better results.

What is the PAC-MANN test, and how does it work?

The PAC-MANN test is a new blood test from Oregon Health & Science University. It looks for changes in protease activity with high accuracy. It needs only a small blood sample and gives quick results.

How accurate is the PAC-MANN test in detecting pancreatic cancer?

The PAC-MANN test is very accurate, with a 98% success rate. It’s a powerful tool for finding pancreatic cancer.

Can combining blood tests improve detection accuracy?

Yes, mixing the PAC-MANN test with CA19-9 boosts accuracy. Together, they achieve an 85% success rate in catching the disease early. Researchers are looking into more ways to combine tests.

What other laboratory tests are used in diagnosing pancreatic cancer?

Other tests include liver function tests, Complete Blood Count (CBC), glucose tests, and pancreatic enzyme tests. These help check how well the pancreas is working and spot any problems.

How is pancreatic cancer treatment effectiveness monitored?

Doctors use blood tests, like the PAC-MANN test, to see how well treatment is working. This helps them adjust the treatment plan as needed.

What is the importance of early detection in pancreatic cancer?

Finding pancreatic cancer early is vital. It gives patients a better chance of successful treatment and a better outlook.

What are the advantages of the PAC-MANN test?

The PAC-MANN test has many benefits. It requires only a small blood sample, gives quick results, is cost-effective, and is easy to access. This makes it great for helping underserved communities.

Reference List

  1. “New blood test identifies hard-to-detect pancreatic cancer with 85% accuracy”
  2. “Novel Blood Test May Help to Identify Pancreatic Ductal Adenocarcinoma at an Earlier Stage”
  3. “Early Detection, Diagnosis, and Staging of Pancreatic Cancer”
  4. “Early detection of pancreatic cancer with a blood test”
  5. “Blood Tests for Pancreatic Cancer Detection”


References

National Center for Biotechnology Information. Evidence-Based Medical Insight. Retrieved from

https://pmc.ncbi.nlm.nih.gov/articles/PMC8311531/

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 510 67 91